So much to take home from the Briefing Presentation, courtesy of...

So much to take home from the Briefing Presentation, courtesy of TonyIndo. The Paul Watt guide to a major re-rating was a highlight particularly for all shareholders in the back seat who are inclined to ask the question 'are we there yet'. Of course we will obviously be there when the market cap is close to $500m but for most posters on this forum - at that stage - we will all want to be comfortably seated even if a little bored and impatient.

PW Re-rating Guide:
1. when a drug candidate enters clinical development
2. when a Big Pharma partner comes back for more
3. when a Big Pharma partner takes up an equity position

So, are we there yet! Settle down in the back because I think we can see the city lights approaching. Dealing only with the last point, the following statement by Nick Woolf is insightful;

"In the next round of deals that we are doing with these companies [there] will be equity stakes, maybe as a precursor to a takeout," said Woolf.